BioInvent International

Board/Management Information • Apr 12, 2018

PRESS RELEASE 12 April 2018

BioInvent recruits Martin Welschof as new CEO

Lund, Sweden – 12 April 2018 – BioInvent International AB (OMXS: BINV) announces today that Dr Martin Welschof has been appointed new President and CEO. He will take office within five months to allow for conclusion of ongoing business discussions at Opsona Therapeutics.

Martin has a broad international experience from executive positions within the biotech industry, including Director of Technology at Axaron Bioscience AG, Heidelberg, Germany and CEO of Affitech (Nasdaq Copenhagen). He is currently CEO of Opsona Therapeutics, based in Dublin, Ireland.

In addition, he has a strong scientific background in the field of antibody technology. He did his postdoctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology both in Heidelberg, Germany. Martin earned his Ph.D. (Dr.rer.nat.) in the field of recombinant antibody technology from the University of Bielefeld, in Germany.

BioInvent's chairman Björn O. Nilsson says in a comment "We are very pleased to recruit a new CEO with broad experience from the international life science industry. Martin's expertise and experience from both science and business will be of importance for the future development of the company, in the efforts to progress the project portfolio, seek new alliances with partners and improving market recognition."

"BioInvent is a very interesting company with broad knowledge and strong technology platforms in the field of antibody therapeutics. The company's scientific leadership and strong project portfolio in the immune oncology area provide exciting business opportunities and I look forward to leading the company," says Dr. Martin Welschof, incoming CEO of BioInvent.

Notes to editors:

About BioInvent

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia and TB-403, in cooperation with Oncurious, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. In December 2016, the Company signed a strategic research collaboration with Pfizer Inc. BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to latestage clinical trials. More information is available at www.bioinvent.com

For further information, please contact:

Björn O. Nilsson Chairman of the Board +46 (0)702 18 15 00 bjorn.nilsson@ursusinnovation.com

Björn Frendéus Acting CEO and Chief Scientific Officer +46 (0)46 286 25 45 +46 (0)708 11 25 45 bjorn.frendeus@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263 Visiting address: Sölvegatan 41 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 info@bioinvent.com www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET, on 12 April, 2018.